Discovery of a junctional epitope antibody that stabilizes IL-6 and gp80 protein:protein interaction and modulates its downstream signaling

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Adams, Ralph ^a   Burnley, Rebecca J ^a   Valenzano, Chiara R ^a   Qureshi, Omar ^a   Doyle, Carl ^a   Lumb, Simon ^a   Del Carmen Lopez, Maria ^a,c   Griffin, Robert ^a   McMillan, David ^a   Taylor, Richard D ^a   Meier, Chris ^a   Mori, Prashant ^a   Griffin, Laura M ^a   Wernery, Ulrich ^b   Kinne, Jörg ^b   Rapecki, Stephen ^a   Baker, Terry S ^a   Lawson, Alastair D G ^a   Wright, Michael ^a   Ettorre, Anna ^a  

^a UCB PHARMA   (Belgium)

^b CENTRAL VETERINARY RESEARCH LABORATORY   (United Arab Emirates)

^c Spandidos Publications UK Ltd ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; STAT3 PROTEIN;

ANIMAL; CAMEL; CHEMISTRY; CHO CELL LINE; CRICETULUS; EPITOPE MAPPING; GENE EXPRESSION PROFILING; HEK293 CELL LINE; HUMAN; IMMUNOLOGY; METABOLISM; PHOSPHORYLATION; PROTEIN TERTIARY STRUCTURE; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES; CAMELUS; CHO CELLS; CRICETULUS; EPITOPE MAPPING; GENE EXPRESSION PROFILING; HEK293 CELLS; HUMANS; INTERLEUKIN-6; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 85011308942     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep37716     Document Type: Article

References (52)

1. Jubb, H., Higueruelo, A. P., Winter, A. & Blundell, T. L. Structural biology and drug discovery for protein-protein interactions. Trends in pharmacological sciences 33, 241-248 (2012).
2. Issafras, H., Corbin, J. A., Goldfine, I. D. & Roell, M. K. Detailed mechanistic analysis of gevokizumab, an allosteric anti-IL-1beta antibody with differential receptor-modulating properties. The Journal of pharmacology and experimental therapeutics 348, 202-215 (2014).
3. Hino, T. et al. G-protein-coupled receptor inactivation by an allosteric inverse-agonist antibody. Nature 482, 237-240 (2012).
4. Meier, C., Cairns-Smith, S. & Schulze, U. Can emerging drug classes improve R&D productivity? Drug discovery today 18, 607-609 (2013).
5. Fischer, G., Rossmann, M. & Hyvonen, M. Alternative modulation of protein-protein interactions by small molecules. Current opinion in biotechnology 35, 78-85 (2015).
6. Lawson, A. D. Antibody-enabled small-molecule drug discovery. Nature reviews. Drug discovery 11, 519-525 (2012).
7. Ward, L. D. et al. Influence of interleukin-6 (IL-6) dimerization on formation of the high affinity hexameric IL-6.receptor complex. The Journal of biological chemistry 271, 20138-20144 (1996).
8. Boulanger, M. J., Chow, D. C., Brevnova, E. E. & Garcia, K. C. Hexameric structure and assembly of the interleukin-6/IL-6 alphareceptor/gp130 complex. Science 300, 2101-2104 (2003).
9. Mullberg, J. et al. The soluble interleukin-6 receptor is generated by shedding. European journal of immunology 23, 473-480 (1993).
10. Rose-John, S., Scheller, J., Elson, G. & Jones, S. A. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. Journal of leukocyte biology 80, 227-236 (2006).
11. Rose-John, S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. International journal of biological sciences 8, 1237-1247 (2012).
12. Galun, E. & Rose-John, S. The regenerative activity of interleukin-6. Methods in molecular biology 982, 59-77 (2013).
13. Mihara, M., Hashizume, M., Yoshida, H., Suzuki, M. & Shiina, M. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond) 122, 143-159 (2012).
14. Hunter, C. A. & Jones, S. A. IL-6 as a keystone cytokine in health and disease. Nature immunology 16, 448-457 (2015).
15. Rose-John, S., Waetzig, G. H., Scheller, J., Grotzinger, J. & Seegert, D. The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert opinion on therapeutic targets 11, 613-624 (2007).
16. Calabrese, L. H. & Rose-John, S. IL-6 biology: implications for clinical targeting in rheumatic disease. Nature reviews. Rheumatology 10, 720-727 (2014).
17. Shaw, S. et al. Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling. mAbs 6, 774-782 (2014).
18. Atreya, R. et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nature medicine 6, 583-588 (2000).
19. Nishimoto, N. et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106, 2627-2632 (2005).
20. Milagre, C. S. et al. Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer. Cancer research 75, 1255-1264 (2015).
21. Fischer, M. et al. I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nature biotechnology 15, 142-145 (1997).
22. Hancock, L. M. A study of camelid antibodies reveal structural features of a cytokine. PhD Thesis University of London (2011).
23. Veverka, V. et al. Conservation of functional sites on interleukin-6 and implications for evolution of signaling complex assembly and therapeutic intervention. The Journal of biological chemistry 287, 40043-40050 (2012).
24. Konermann, L., Pan, J. & Liu, Y. H. Hydrogen exchange mass spectrometry for studying protein structure and dynamics. Chemical Society reviews 40, 1224-1234 (2011).
25. Somers, W., Stahl, M. & Seehra, J. S. 1.9 A crystal structure of interleukin 6: implications for a novel mode of receptor dimerization and signaling. The EMBO journal 16, 989-997 (1997).
26. Heinrich, P. C. et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. The Biochemical journal 374, 1-20 (2003).
27. Wang, Y., van Boxel-Dezaire, A. H., Cheon, H., Yang, J. & Stark, G. R. STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor. Proceedings of the National Academy of Sciences of the United States of America 110, 16975-16980 (2013).
28. Rakemann, T. et al. The designer cytokine hyper-interleukin-6 is a potent activator of STAT3-dependent gene transcription in vivo and in vitro. The Journal of biological chemistry 274, 1257-1266 (1999).
29. Romano, M. et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 6, 315-325 (1997).
30. Diskin, R., Marcovecchio, P. M. & Bjorkman, P. J. Structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity. Nature structural & molecular biology 17, 608-613 (2010).
31. Impagliazzo. A. et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 349(6254), 1301-1306 (2015).
32. Lee, J. E. et al. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature. 454(7201), 177-82 (2008).
33. Yu, H., Pardoll, D. & Jove, R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nature reviews. Cancer 9, 798-809 (2009).
34. Koch, A. E. et al. Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. The Journal of clinical investigation 90, 772-779 (1992).
35. Hueber, W. et al. Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines. Annals of the rheumatic diseases 66, 712-719 (2007).
36. Stamatovic, S. M., Keep, R. F., Kunkel, S. L. & Andjelkovic, A. V. Potential role of MCP-1 in endothelial cell tight junction 'opening': signaling via Rho and Rho kinase. Journal of cell science 116, 4615-4628 (2003).
37. Desai, T. R., Leeper, N. J., Hynes, K. L. & Gewertz, B. L. Interleukin-6 causes endothelial barrier dysfunction via the protein kinase C pathway. The Journal of surgical research 104, 118-123 (2002).
38. Braun, D. A., Fribourg, M. & Sealfon, S. C. Cytokine response is determined by duration of receptor and signal transducers and activators of transcription 3 (STAT3) activation. The Journal of biological chemistry 288, 2986-2993 (2013).
39. Wuestefeld, T. et al. Interleukin-6/glycoprotein 130-dependent pathways are protective during liver regeneration. The Journal of biological chemistry 278, 11281-11288 (2003).
40. Best, D. H., Butz, G. M. & Coleman, W. B. Cytokine-dependent activation of small hepatocyte-like progenitor cells in retrorsineinduced rat liver injury. Experimental and molecular pathology 88, 7-14 (2010).
41. Tickle, S. et al. High-throughput screening for high affinity antibodies. JALA 14, 303-307 (2009).
42. Lightwood, D. et al. The discovery, engineering and characterisation of a highly potent anti-human IL-13 fab fragment designed for administration by inhalation. Journal of molecular biology 425, 577-593 (2013).
43. Jerabek-Willemsen, M., Wienken, C. J., Braun, D., Baaske, P. & Duhr, S. Molecular interaction studies using microscale thermophoresis. Assay and drug development technologies 9, 342-353 (2011).
44. Abdiche, Y. N., Lindquist, K. C., Stone, D. M., Rajpal, A. & Pons, J. Label-free epitope binning assays of monoclonal antibodies enable the identification of antigen heterogeneity. Journal of immunological methods 382, 101-116 (2012).
45. Varghese, J. N. et al. Structure of the extracellular domains of the human interleukin-6 receptor alpha-chain. Proceedings of the National Academy of Sciences of the United States of America 99, 15959-15964 (2002).
46. Kabsch, W. Xds. Acta crystallographica. Section D, Biological crystallography 66, 125-132 (2010).
47. McCoy, A. J. et al. Phaser crystallographic software. Journal of applied crystallography 40, 658-674 (2007).
48. Brunger, A. T. et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta crystallographica. Section D, Biological crystallography 54, 905-921 (1998).
49. Brunger, A. T. Version 1.2 of the Crystallography and NMR system. Nature protocols 2, 2728-2733 (2007).
50. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta crystallographica. Section D, Biological crystallography 60, 2126-2132 (2004).
51. Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta crystallographica. Section D, Biological crystallography 66, 12-21 (2010).
52. Krissinel, E. & Henrick, K. Inference of macromolecular assemblies from crystalline state. Journal of molecular biology 372, 774-797 (2007).